This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

RegenETP Yönetim

Yönetim kriter kontrolleri 4/4

RegenETP's CEO is Richard Hague, appointed in Apr 2020, has a tenure of 3.42 years. total yearly compensation is $479.81K, comprised of 93.5% salary and 6.5% bonuses, including company stock and options. directly owns 0.62% of the company’s shares, worth €2.70K. The average tenure of the management team and the board of directors is 4.3 years and 6.3 years respectively.

Anahtar bilgiler

Richard Hague

İcra Kurulu Başkanı

US$479.8k

Toplam tazminat

CEO maaş yüzdesi	93.5%
CEO görev süresi	3.4yrs
CEO sahipliği	0.6%
Yönetim ortalama görev süresi	4.3yrs
Yönetim Kurulu ortalama görev süresi	6.3yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Richard Hague'un ücretlendirmesi RegenETP'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Mar 31 2023	n/a	n/a	-US$8m
Dec 31 2022	US$480k	US$449k	-US$8m
Sep 30 2022	n/a	n/a	-US$16m
Jun 30 2022	n/a	n/a	-US$13m
Mar 31 2022	n/a	n/a	-US$17m
Dec 31 2021	US$1m	US$359k	-US$30m
Sep 30 2021	n/a	n/a	-US$32m
Jun 30 2021	n/a	n/a	-US$38m
Mar 31 2021	n/a	n/a	-US$47m
Dec 31 2020	US$996k	US$358k	-US$43m
Sep 30 2020	n/a	n/a	-US$54m
Jun 30 2020	n/a	n/a	-US$70m
Mar 31 2020	n/a	n/a	-US$80m
Dec 31 2019	US$2m	US$273k	-US$92m

Tazminat ve Piyasa: Richard's total compensation ($USD479.81K) is about average for companies of similar size in the German market ($USD418.12K).

Tazminat ve Kazançlar: Richard's compensation has been consistent with company performance over the past year.

CEO

Richard Hague (63 yo)

3.4yrs

Görev süresi

US$479,808

Tazminat

Mr. Richard Hague is Director of Remedium Bio, Inc since 2022. He serves as President at PolarityTE, Inc. since August 2019 and its Chief Executive Officer since August 2021 and also served as its Chief Op...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Richard Hague	President	3.4yrs	US$479.81k	0.62% € 2.7k
Nikolai Sopko	Chief Scientific Officer and VP of R&D	5.2yrs	Veri yok	Veri yok
Rich Haerle	Vice President of Investor Relations & Strategy	5.3yrs	Veri yok	Veri yok
Mark Lehman	Chief Legal Officer	no data	Veri yok	Veri yok
Angela Ziegler	Vice President of Marketing & Public Relations	no data	Veri yok	Veri yok
Alain Adam	Vice President of Sales	5.2yrs	Veri yok	Veri yok
Jon Anthony Burrows	Senior VP of Corporate Development & President of Contract Services	no data	Veri yok	Veri yok
Ryan Mathis	Chief Medical Officer	2yrs	Veri yok	Veri yok
Kolby Day	Senior Vice President of Manufacturing Operations	less than a year	Veri yok	Veri yok

4.3yrs

Ortalama Görev Süresi

Deneyimli Yönetim: NJT's management team is considered experienced (4.3 years average tenure).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Richard Hague	President	less than a year	US$479.81k	0.62% € 2.7k
Michael Callahan	Member of Clinical Advisory board	no data	Veri yok	Veri yok
Stephen Milner	Member of Clinical Advisory Board	6.8yrs	Veri yok	Veri yok
Michael Grant	Member of Clinical Advisory Board	6.8yrs	Veri yok	Veri yok
Anand Kumar	Member of Clinical Advisory Board	6.8yrs	Veri yok	Veri yok
Anthony Tufaro	Member of Clinical Advisory Board	no data	Veri yok	Veri yok
Trinity Bivalacqua	Member of Clinical Advisory Board	no data	Veri yok	Veri yok
Shannath Merbs	Member of Clinical Advisory Board	no data	Veri yok	Veri yok
Ryan Katz	Member of Clinical Advisory Board	no data	Veri yok	Veri yok
Martin Robson	Member of Clinical Advisory Board	6.3yrs	Veri yok	Veri yok
William Hickerson	Member of Clinical Advisory Board	6.3yrs	Veri yok	Veri yok
Jeffrey Shupp	Member of Clinical Advisory Board	6.3yrs	Veri yok	Veri yok

6.3yrs

Ortalama Görev Süresi

Deneyimli Yönetim Kurulu: NJT's board of directors are considered experienced (6.3 years average tenure).

This company listing is no longer active

RegenETP Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

PolarityTE, Inc. Announces Resignation of Jacob Patterson as Chief Financial Officer

Polarityte, Inc. Appoints Jeff Dyer as A Member of the Board of Directors

Insufficient new directors

PolarityTE, Inc. Announces Resignation of Jeff Dyer from its Board of Directors

Independent Chairman of the Board recently bought €212k worth of stock

Recent updates

RegenETP, Inc. announced that it expects to receive $22.5 million in funding from Avenue Capital Group, LLC

PolarityTE Screens First Subject in Phase III Pivotal Study Evaluating Investigational New Drug SkinTE® in Diabetic Foot Ulcers

PolarityTE, Inc. Announces Resignation of Jacob Patterson as Chief Financial Officer

PolarityTE, Inc. announced delayed 10-Q filing

PolarityTE, Inc. Files Form 15

Nasdaq to Delist the Common Stock of PolarityTE

PolarityTE, Inc.(OTCPK:PTEI.Q) dropped from NASDAQ Composite Index

PolarityTE's Common Stock To Be Delisted From Nasdaq

First quarter 2023 earnings released: US$0.58 loss per share (vs US$1.12 loss in 1Q 2022)

Forecast to breakeven in 2025

Polarityte, Inc. Appoints Jeff Dyer as A Member of the Board of Directors

Insufficient new directors

Forecast to breakeven in 2025

Third quarter 2022 earnings released: US$0.47 loss per share (vs US$0.31 loss in 3Q 2021)

Third quarter 2022 earnings released: US$0.47 loss per share (vs US$0.31 loss in 3Q 2021)

Michael Brauser submitted a non-binding offer to acquire the remaining stake in PolarityTE, Inc. (NasdaqCM:PTE).

PolarityTE, Inc. Receives Deficiency Letter the Listing Qualifications Department of Nasdaq

PolarityTE, Inc. Announces Resignation of Jeff Dyer from its Board of Directors

Second quarter 2022 earnings released: US$0.013 loss per share (vs US$0.99 loss in 2Q 2021)

PolarityTE, Inc. to Report Q2, 2022 Results on Aug 11, 2022

First quarter 2022 earnings released: US$0.045 loss per share (vs US$0.23 loss in 1Q 2021)

PolarityTE, Inc. Announces FDA Regenerative Medicine Advanced Therapy Designation Granted to SkinTE(R)

PolarityTE, Inc. to Report Q1, 2022 Results on May 16, 2022

Full year 2021 earnings released: US$0.38 loss per share (vs US$1.11 loss in FY 2020)

PolarityTE, Inc. Announces Results from Multi-Center Randomized Controlled Trial Evaluating Treatment of Venous Leg Ulcers with Its Investigational Product SkinTE plus standard of care vs SOC alone

PolarityTE, Inc. Announces Allowance of Fourth U.S. Patent

PolarityTE, Inc Announces U.S. FDA Approval of IND for Pivotal Phase 3 Study of SkinTE® to Support Chronic Cutaneous Ulcer Indication

PolarityTE, Inc. Announces Submission of Complete Response to Fda's Clinical Hold Correspondence for Skinte® Investigational New Drug Application

Third quarter 2021 earnings released: US$0.013 loss per share (vs US$0.18 loss in 3Q 2020)

Gainey Mckenna & Egleston Announces A Class Action Lawsuit Filed Against PolarityTE, Inc

Independent Director Minnie Baylor-Henry has left the company

PolarityTE Provides Update on U.S. FDA Investigational New Drug Application for SkinTE®

PolarityTE Receives A Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Second quarter 2021 earnings released: US$0.04 loss per share (vs US$0.33 loss in 2Q 2020)

Independent Chairman of the Board recently bought €212k worth of stock

First quarter 2021 earnings released: US$0.23 loss per share (vs US$0.40 loss in 1Q 2020)

PolarityTE, Inc. Updates on SkinTE Biologic License Application

PolarityTE Announces Diabetic Foot Ulcer Trial Met Primary and Secondary Endpoint

PolarityTE, Inc. to Report Fiscal Year 2020 Results on Mar 30, 2021

PolarityTE, Inc. Announces Submission of an Investigational New Drug Application

New 90-day high: €1.23

PolarityTE Announces Completion of Target Enrollment in Diabetic Foot Ulcer Trial

PolarityTE, Inc. has completed a Follow-on Equity Offering in the amount of $10.000001 million.

New 90-day high: €0.98

New 90-day low: €0.53

Polarityte Announces Dismissal of Securities Class Action Complaint with Prejudice

New 90-day low: €0.57

Third quarter 2020 earnings released: US$0.18 loss per share

Revenue beats expectations

PolarityTE Announces Successful Completion of Initial Pre-IND Interaction with U.S. Food and Drug Administration for SkinTE®

PolarityTE, Inc. to Report Q3, 2020 Results on Nov 09, 2020

New 90-day low: €0.82

PolarityTE Receives NIH Grant for a Point-of-Care Device to Treat Chronic Wounds

New 90-day low: €0.85

PolarityTE, Inc. Announces SkinTE™ Health Economics — DFU Interim Analysis Data Demonstrates Potential for Cost Savings and Improved Wound Closure

New 90-day low - €0.94

First half earnings released

New 90-day high - €1.47

PolarityTE, Inc.(NasdaqCM:PTE) dropped from Russell Small Cap Completeness Index

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi